Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 4306579, 9 pages
https://doi.org/10.1155/2018/4306579
Research Article

Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma

1State Key Laboratory of Oral Diseases, Chengdu 610041, China
2School of Basic Medical Science, Zhengzhou University, Zhengzhou 450001, China

Correspondence should be addressed to Ziming Dong; nc.ude.uzz@mzgnod

Received 9 November 2017; Revised 6 January 2018; Accepted 15 January 2018; Published 19 March 2018

Academic Editor: Mirella Falconi

Copyright © 2018 Yi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. PosthumaDeBoer, M. A. Witlox, G. J. L. Kaspers, and B. J. Van Royen, “Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature,” Clinical and Experimental Metastasis, vol. 28, no. 5, pp. 493–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Tang, W. Wan, L. Wang, S. Ji, and J. Zhang, “MicroRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 12, pp. 15611–15621, 2015. View at Google Scholar · View at Scopus
  3. X. Li, X. Liu, J. Fang, H. Li, and J. Chen, “MicroRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 11, pp. 20157–20167, 2015. View at Google Scholar · View at Scopus
  4. N. Tang, W.-X. Song, J. Luo, R. C. Haydon, and T.-C. He, “Osteosarcoma development and stem cell differentiation,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2114–2130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Ottaviani and N. Jaffe, “The epidemiology of osteosarcoma,” Cancer Treatment and Research, vol. 152, pp. 3–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Shi, R. L. Lan, X. Tao et al., “Vitronectin significantly influences prognosis in osteosarcoma,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 9, pp. 11364–11371, 2015. View at Google Scholar
  7. M.-F. Heymann, H. K. Brown, and D. Heymann, “Drugs in early clinical development for the treatment of osteosarcoma,” Expert Opinion on Investigational Drugs, vol. 25, no. 11, pp. 1265–1280, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kubo, S. Shimose, J. Fujimori, T. Furuta, and M. Ochi, “Quantitative (201)thallium scintigraphy for prediction of histological response to neoadjuvant chemotherapy in osteosarcoma; Systematic review and meta-analysis,” Surgical Oncology, vol. 24, no. 3, pp. 194–199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Luetke, P. A. Meyers, I. Lewis, and H. Juergens, “Osteosarcoma treatment—where do we stand? A state of the art review,” Cancer Treatment Reviews, vol. 40, no. 4, pp. 523–532, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. W. Bishop, K. A. Janeway, and R. Gorlick, “Future directions in the treatment of osteosarcoma,” Current Opinion in Pediatrics, vol. 28, no. 1, pp. 26–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. Shaikh, F. Li, M. Li et al., “Present advances and future perspectives of molecular targeted therapy for osteosarcoma,” International Journal of Molecular Sciences, vol. 17, no. 4, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Jiang, Y. Yang, Y. Yang et al., “Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune,” Biomedicine & Pharmacotherapy, vol. 96, pp. 378–383, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Li, J. Ni, M. Li et al., “Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy,” Drug Delivery, vol. 24, no. 1, pp. 1617–1630, 2017. View at Publisher · View at Google Scholar
  14. J. Jiang, Z. Yuan, Y. Sun, Y. Bu, W. Li, and Z. Fei, “Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway,” Biomedicine & Pharmacotherapy, vol. 96, pp. 619–625, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Polivka Jr. and F. Janku, “Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway,” Pharmacology & Therapeutics, vol. 142, no. 2, pp. 164–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J.-W. Kim, S.-Y. Jung, Y.-H. Kwon et al., “Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells,” Cancer Biology & Therapy, vol. 13, no. 7, pp. 504–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Sharifi, A. M. Nayebi, S. Farajnia, and R. Haddadi, “Effect of buspirone, fluoxetine and 8-OH-DPAT on striatal expression of bax, caspase-3 and Bcl-2 proteins in 6-hydroxydopamine-induced hemi-parkinsonian rats,” Advanced Pharmaceutical Bulletin (APB), vol. 5, no. 4, pp. 491–495, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Chen, J. Wang, Q. Qin et al., “Mono-2-ethylhexyl phthalate induced loss of mitochondrial membrane potential and activation of Caspase3 in HepG2 cells,” Environmental Toxicology and Pharmacology, vol. 33, no. 3, pp. 421–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Ouyang, Z. Shi, S. Zhao et al., “Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis,” Cell Proliferation, vol. 45, no. 6, pp. 487–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. N.-K. Niu, Z.-L. Wang, S.-T. Pan et al., “Pro-apoptotic and pro-autophagic effects of the aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway,” Drug Design, Development and Therapy, vol. 9, pp. 1555–1584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Yu, X.-J. Jia, Q.-F. Zong et al., “Remote ischemic postconditioning protects the heart by upregulating ALDH2 expression levels through the PI3K/Akt signaling pathway,” Molecular Medicine Reports, vol. 10, no. 1, pp. 536–542, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Ahmad, B. Biersack, Y. Li et al., “Deregulation of PI3K/Akt/mTOR signaling pathways by Isoflavones and its implication in cancer treatment,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 7, pp. 1014–1024, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Zhang, X.-H. Yu, Y.-G. Yan, C. Wang, and W.-J. Wang, “PI3K/Akt signaling in osteosarcoma,” Clinica Chimica Acta, vol. 444, pp. 182–192, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Wang, S. Xu, Y. Wu, and J. Zhang, “Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signalling pathway,” Bioscience Reports, vol. 36, no. 6, Article ID e00405, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Yang, D. Cheng, S. Zhou, B. Zhu, T. Hu, and Q. Yang, “Overexpression of X-Box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 28635–28646, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Chen, D. Yao, H. Yuan et al., “Dipsacus asperoides polysaccharide induces apoptosis in osteosarcoma cells by modulating the PI3K/Akt pathway,” Carbohydrate Polymers, vol. 95, no. 2, pp. 780–784, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J.-Q. Dai, Y.-G. Huang, and A.-N. He, “Dihydromethysticin kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 5, pp. 4356–4366, 2015. View at Google Scholar · View at Scopus
  29. J. E. Thompson and C. B. Thompson, “Putting the rap on Akt,” Journal of Clinical Oncology, vol. 22, no. 20, pp. 4217–4226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. R. Datta, A. Brunet, and M. E. Greenberg, “Cellular survival: a play in three akts,” Genes & Development, vol. 13, no. 22, pp. 2905–2927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. S. G. Kennedy, A. J. Wagner, S. D. Conzen et al., “The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal,” Genes & Development, vol. 11, no. 6, pp. 701–713, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. M. H. Cardone, N. Roy, H. R. Stennicke et al., “Regulation of cell death protease caspase-9 by phosphorylation,” Science, vol. 282, no. 5392, pp. 1318–1321, 1998. View at Publisher · View at Google Scholar · View at Scopus